233 related articles for article (PubMed ID: 19022819)
1. The PI3K/Akt/mTOR pathway in innate immune cells: emerging therapeutic applications.
Weichhart T; Säemann MD
Ann Rheum Dis; 2008 Dec; 67 Suppl 3():iii70-4. PubMed ID: 19022819
[TBL] [Abstract][Full Text] [Related]
2. Human CD34-derived myeloid dendritic cell development requires intact phosphatidylinositol 3-kinase-protein kinase B-mammalian target of rapamycin signaling.
van de Laar L; Buitenhuis M; Wensveen FM; Janssen HL; Coffer PJ; Woltman AM
J Immunol; 2010 Jun; 184(12):6600-11. PubMed ID: 20488790
[TBL] [Abstract][Full Text] [Related]
3. IGF-1-stimulated protein synthesis in oligodendrocyte progenitors requires PI3K/mTOR/Akt and MEK/ERK pathways.
Bibollet-Bahena O; Almazan G
J Neurochem; 2009 Jun; 109(5):1440-51. PubMed ID: 19453943
[TBL] [Abstract][Full Text] [Related]
4. The TSC-mTOR signaling pathway regulates the innate inflammatory response.
Weichhart T; Costantino G; Poglitsch M; Rosner M; Zeyda M; Stuhlmeier KM; Kolbe T; Stulnig TM; Hörl WH; Hengstschläger M; Müller M; Säemann MD
Immunity; 2008 Oct; 29(4):565-77. PubMed ID: 18848473
[TBL] [Abstract][Full Text] [Related]
5. Complement C1q chemoattracts human dendritic cells and enhances migration of mature dendritic cells to CCL19 via activation of AKT and MAPK pathways.
Liu S; Wu J; Zhang T; Qian B; Wu P; Li L; Yu Y; Cao X
Mol Immunol; 2008 Dec; 46(2):242-9. PubMed ID: 18838169
[TBL] [Abstract][Full Text] [Related]
6. Leptin exerts an anti-apoptotic effect on human dendritic cells via the PI3K-Akt signaling pathway.
Mattioli B; Giordani L; Quaranta MG; Viora M
FEBS Lett; 2009 Apr; 583(7):1102-6. PubMed ID: 19250936
[TBL] [Abstract][Full Text] [Related]
7. The multiple facets of mTOR in immunity.
Weichhart T; Säemann MD
Trends Immunol; 2009 May; 30(5):218-26. PubMed ID: 19362054
[TBL] [Abstract][Full Text] [Related]
8. Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises.
Yap TA; Garrett MD; Walton MI; Raynaud F; de Bono JS; Workman P
Curr Opin Pharmacol; 2008 Aug; 8(4):393-412. PubMed ID: 18721898
[TBL] [Abstract][Full Text] [Related]
9. Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.
McMillin DW; Ooi M; Delmore J; Negri J; Hayden P; Mitsiades N; Jakubikova J; Maira SM; Garcia-Echeverria C; Schlossman R; Munshi NC; Richardson PG; Anderson KC; Mitsiades CS
Cancer Res; 2009 Jul; 69(14):5835-42. PubMed ID: 19584292
[TBL] [Abstract][Full Text] [Related]
10. Mammalian target of rapamycin (mTOR) orchestrates the defense program of innate immune cells.
Schmitz F; Heit A; Dreher S; Eisenächer K; Mages J; Haas T; Krug A; Janssen KP; Kirschning CJ; Wagner H
Eur J Immunol; 2008 Nov; 38(11):2981-92. PubMed ID: 18924132
[TBL] [Abstract][Full Text] [Related]
11. Glucagon-like peptide-1 (GLP-1) protects against methylglyoxal-induced PC12 cell apoptosis through the PI3K/Akt/mTOR/GCLc/redox signaling pathway.
Kimura R; Okouchi M; Fujioka H; Ichiyanagi A; Ryuge F; Mizuno T; Imaeda K; Okayama N; Kamiya Y; Asai K; Joh T
Neuroscience; 2009 Sep; 162(4):1212-9. PubMed ID: 19463904
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of class I phosphoinositide 3-kinase activity impairs proliferation and triggers apoptosis in acute promyelocytic leukemia without affecting atra-induced differentiation.
Billottet C; Banerjee L; Vanhaesebroeck B; Khwaja A
Cancer Res; 2009 Feb; 69(3):1027-36. PubMed ID: 19176369
[TBL] [Abstract][Full Text] [Related]
13. KAI1/CD82 decreases Rac1 expression and cell proliferation through PI3K/Akt/mTOR pathway in H1299 lung carcinoma cells.
Choi UJ; Jee BK; Lim Y; Lee KH
Cell Biochem Funct; 2009 Jan; 27(1):40-7. PubMed ID: 19107873
[TBL] [Abstract][Full Text] [Related]
14. 'Vive la Résistance!'--the PI3K-Akt pathway can determine target sensitivity to regulatory T cell suppression.
Wohlfert EA; Clark RB
Trends Immunol; 2007 Apr; 28(4):154-60. PubMed ID: 17329168
[TBL] [Abstract][Full Text] [Related]
15. RAPping production of type I interferon in pDCs through mTOR.
Costa-Mattioli M; Sonenberg N
Nat Immunol; 2008 Oct; 9(10):1097-9. PubMed ID: 18800159
[TBL] [Abstract][Full Text] [Related]
16. Phosphatidylinositol-3-kinase/Akt signaling pathway and kidney cancer, and the therapeutic potential of phosphatidylinositol-3-kinase/Akt inhibitors.
Porta C; Figlin RA
J Urol; 2009 Dec; 182(6):2569-77. PubMed ID: 19836781
[TBL] [Abstract][Full Text] [Related]
17. Microarray analyses of the effects of NF-kappaB or PI3K pathway inhibitors on the LPS-induced gene expression profile in RAW264.7 cells: synergistic effects of rapamycin on LPS-induced MMP9-overexpression.
Mendes Sdos S; Candi A; Vansteenbrugge M; Pignon MR; Bult H; Boudjeltia KZ; Munaut C; Raes M
Cell Signal; 2009 Jul; 21(7):1109-22. PubMed ID: 19285553
[TBL] [Abstract][Full Text] [Related]
18. 9-Aminoacridine-based anticancer drugs target the PI3K/AKT/mTOR, NF-kappaB and p53 pathways.
Guo C; Gasparian AV; Zhuang Z; Bosykh DA; Komar AA; Gudkov AV; Gurova KV
Oncogene; 2009 Feb; 28(8):1151-61. PubMed ID: 19137016
[TBL] [Abstract][Full Text] [Related]
19. Amyloid-beta interrupts the PI3K-Akt-mTOR signaling pathway that could be involved in brain-derived neurotrophic factor-induced Arc expression in rat cortical neurons.
Chen TJ; Wang DC; Chen SS
J Neurosci Res; 2009 Aug; 87(10):2297-307. PubMed ID: 19301428
[TBL] [Abstract][Full Text] [Related]
20. Growth suppressive cytokines and the AKT/mTOR pathway.
Kroczynska B; Kaur S; Platanias LC
Cytokine; 2009; 48(1-2):138-43. PubMed ID: 19682919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
